Use of Fc-engineered antibodies as clearing agents to increase contrast during PET

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1204-1207

  Swiercz, Rafal ^a   Chiguru, Srinivas ^b   Tahmasbi, Amir ^c   Ramezani, Saleh M ^b   Hao, Guiyang ^b   Challa, Dilip K ^a   Lewis, Matthew A ^b   Kulkarni, Padmakar V ^b   Sun, Xiankai ^b   Ober, Raimund J ^a,c   Mason, Ralph P ^b   Ward, E Sally ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c The University of Texas at Dallas   (United States)

Author keywords

Breast cancer; Engineered antibodies; FcRn; PET

Indexed keywords

ABDEG; IMMUNOGLOBULIN FC FRAGMENT; IODINE PERTUZUMAB I 124; IODINE PERTUZUMAB I 125; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; MONOCLONAL ANTIBODY; PERTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY LABELING; ARTICLE; BIOACCUMULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; FEMALE; IMAGE ENHANCEMENT; IMAGE QUALITY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOASSAY; RADIOISOTOPE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; DIAGNOSTIC USE; HALF LIFE TIME; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN ENGINEERING; SIGNAL NOISE RATIO; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTORS, FC; SIGNAL-TO-NOISE RATIO;

EID: 84904120482     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136481     Document Type: Article

References (20)

1. Goldstein R, Sosabowski J, Vigor K, Chester K, Meyer T. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther. 2013;13:359-373.
2. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
3. Jaggi JS, Carrasquillo JA, Seshan SV, et al. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest. 2007;117:2422-2430. (Pubitemid 47494344)
4. Goldenberg DM, Chang CH, Rossi EA, McBride JW, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2:523-540.
5. Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer. 2010;116:1126-1133.
6. Ward ES, Ober RJ. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. Adv Immunol. 2009;103:77-115.
7. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol. 2004;172:2021-2029. (Pubitemid 38182347)
8. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA. 2004;101:11076-11081. (Pubitemid 38989586)
9. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23:1283-1288. (Pubitemid 41486856)
10. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC Class I-related receptor, FcRn, reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA. 2009;106:2788-2793.
11. Patel DA, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ, Ward ES. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol. 2011;187:1015-1022.
12. Challa DK, Bussmeyer U, Khan T, et al. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. MAbs. 2013;5:655-659.
13. Gazdar AF, Kurvari V, Virmani A, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998;78:766-774. (Pubitemid 28530401)
14. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.
15. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-3892.
16. Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50:1500-1508.
17. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med. 1999;40:1536-1546. (Pubitemid 29428939)
18. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic. 2009;10:600-614.
19. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006;253(suppl 5):V18-V24.
20. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol. 2007;19:646-651. (Pubitemid 350236813)